Anika Therapeutics

Update in progress

ANIK (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Anika Therapeutics, Inc. is a joint preservation company focused on early intervention orthopedics in the U.S., Europe, and abroad. It offers HA-based OA pain management products such as Monovisc, Orthovisc, and Cingal, plus regenerative solutions like an HA scaffold with fixation, Hyalofast, Tactoset, and Integrity. The portfolio also includes Hyvisc and Hyalobarrier, ophthalmic products, Anikavisc, and Nuvisc. Founded in 1983, it is headquartered in Bedford, Massachusetts.

Company score

Sentiment: -0.10; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.11; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.15; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.06; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.02; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive